

ESMO Breast Cancer 2022 Industry Satellite Symposium

GILEAD Promotional Symposium

# TNBC: See Beyond the Negatives

*Evolving the standard of care*

Tuesday, 3 May 2022 11:30 AM-12:30 PM (CEST) Munich Hall, Hub 27, Berlin

## Our expert faculty



*Welcome & introduction*  
**Andreas Schneeweiss**  
(Chair)



*Evolving treatment landscape in TNBC*  
**Joseph Gligorov**



*Sacituzumab govitecan<sup>®</sup>\**  
*Setting a new standard of care for mTNBC*  
**Sara M. Tolaney**

*We look forward to welcoming you all!*

\*INDICATION: TRODELVY<sup>®</sup> (sacituzumab govitecan) as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic triple negative breast cancer (mTNBC) who have received two or more prior systemic therapies, including at least one of them for advanced disease.

▼ This medicinal product is subject to additional monitoring. Please see Summary of Product Characteristics for full details on managing adverse reaction:  
[https://www.ema.europa.eu/en/documents/product-information/trodelvy-epar-product-information\\_en.pdf](https://www.ema.europa.eu/en/documents/product-information/trodelvy-epar-product-information_en.pdf)

This symposium is sponsored and organised by Gilead and Gilead's medicines will be discussed at this meeting.  
Date of preparation: March 2022 IHQ-TRO-0122

